Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat

Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

February 27, 2020 4:05 PM EST

- REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing -

- Multiple clinical presentations reviewed at the 61st American Society of Hematology (ASH) Annual Meeting; MEDALIST trial results published in New England Journal of Medicine -

- The PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH) achieved... More